Severe hypoglycemia and risks of vascular events and death.
暂无分享,去创建一个
Mark Woodward | Bruce Neal | Diederick E Grobbee | Stephen MacMahon | Qiang Li | Bastiaan E de Galan | Sophia Zoungas | Michel Marre | Laurent Billot | John Chalmers | Andre Pascal Kengne | M. Woodward | D. Grobbee | A. Kengne | S. Heller | M. Marre | S. MacMahon | J. Chalmers | B. Neal | T. Ninomiya | S. Zoungas | Anushka Patel | Qiang Li | B. D. de Galan | L. Billot | Anushka Patel | Simon Heller | Toshiharu Ninomiya
[1] R. Heine,et al. Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study , 2010, The Lancet.
[2] Michael E. Miller,et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study , 2010, BMJ : British Medical Journal.
[3] Thomas E. Moritz,et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes , 2009, Diabetologia.
[4] H. Krumholz,et al. Relationship between spontaneous and iatrogenic hypoglycemia and mortality in patients hospitalized with acute myocardial infarction. , 2009, JAMA.
[5] R. Freeman,et al. Antecedent Hypoglycemia Impairs Autonomic Cardiovascular Function , 2009, Diabetes.
[6] Grant D. Huang,et al. Glucose control and vascular complications in veterans with type 2 diabetes. , 2009, The New England journal of medicine.
[7] B. Howard,et al. Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials , 2009, Diabetes Care.
[8] J. Nunnelee. Review of an article: The ADVANCE Collaborative Group. (2008). Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. NEJM 2008;358:2560-2572. , 2008 .
[9] B. Frier,et al. Vascular disease and diabetes: is hypoglycaemia an aggravating factor? , 2008, Diabetes/metabolism research and reviews.
[10] Diederick Grobbee,et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. , 2008, The New England journal of medicine.
[11] Michael E. Miller,et al. Effects of intensive glucose lowering in type 2 diabetes. , 2008, The New England journal of medicine.
[12] H. Krumholz,et al. Glucometrics in Patients Hospitalized With Acute Myocardial Infarction: Defining the Optimal Outcomes-Based Measure of Risk , 2008, Circulation.
[13] M. Pencina,et al. Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.
[14] P. Schwartz,et al. Baroreflex sensitivity predicts long-term cardiovascular mortality after myocardial infarction even in patients with preserved left ventricular function. , 2007, Journal of the American College of Cardiology.
[15] Anushka Patel,et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial , 2007, The Lancet.
[16] P. Cryer. Mechanisms of hypoglycemia-associated autonomic failure and its component syndromes in diabetes. , 2005, Diabetes.
[17] R. Giugliano,et al. U-shaped relationship of blood glucose with adverse outcomes among patients with ST-segment elevation myocardial infarction. , 2005, Journal of the American College of Cardiology.
[18] Darren K Mcguire,et al. Association between hyper- and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute coronary events. , 2005, European heart journal.
[19] Braxton D Mitchell,et al. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. , 2003, Diabetes care.
[20] Benjamin Cheong,et al. Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring. , 2002, Diabetes care.
[21] Daniel Zelterman,et al. Modeling Survival Data: Extending the Cox Model , 2002, Technometrics.
[22] Stephen MacMahon,et al. Reliable assessment of the effects of treatment on mortality and major morbidity, II: observational studies , 2001, The Lancet.
[23] J. Bigger,et al. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction , 1998, The Lancet.
[24] R. J. Hayes,et al. United Kingdom Prospective Diabetes Study 24: A 6-Year, Randomized, Controlled Trial Comparing Sulfonylurea, Insulin, and Metformin Therapy in Patients with Newly Diagnosed Type 2 Diabetes That Could Not Be Controlled with Diet Therapy , 1998, Annals of Internal Medicine.
[25] D. Hosmer,et al. A comparison of goodness-of-fit tests for the logistic regression model. , 1997, Statistics in medicine.
[26] M. Feinglos,et al. Hypoglycemia-Induced Angina Pectoris in a Patient with Diabetes Mellitus , 1994, Annals of Internal Medicine.
[27] J. Fleiss,et al. The ability of several short-term measures of RR variability to predict mortality after myocardial infarction. , 1993, Circulation.
[28] E. DeLong,et al. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.
[29] Michael E. Miller,et al. ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY GROUP. EFFECTS OF INTENSIVE GLUCOSE LOWERING IN TYPE 2 DIABETES , 2010 .
[30] M. Orho-Melander,et al. Functional characterisation of the glucokinase regulatory protein gene variant P446L shows diminished regulation by fructose-6 phosphate resulting in increased glucokinase activity , 2009 .
[31] Peter M. Rothwell,et al. Reliable assessment of the effects of treatments on mortality and major morbidity , 2007 .